Esperion Therapeutics, Inc. (ESPR)
ESPR Stock Price Chart
Explore Esperion Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ESPR price movements and trends.
ESPR Company Profile
Discover essential business fundamentals and corporate details for Esperion Therapeutics, Inc. (ESPR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jun 2013
Employees
304.00
Website
https://www.esperion.comCEO
Sheldon L. Koenig
Description
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
ESPR Financial Timeline
Browse a chronological timeline of Esperion Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.02, while revenue estimate is $92.48m.
Dividend declared on 13 Jul 2026
A dividend of $3.16 per share was announced, adjusted to $3.16.
Earnings released on 8 May 2026
EPS came in at -$0.10 falling short of the estimated -$0.04 by -150.00%, while revenue for the quarter reached $80.10m , missing expectations by -5.23%.
Earnings released on 10 Mar 2026
EPS came in at $0.22 falling short of the estimated $0.23 by -4.35%, while revenue for the quarter reached $168.45m , beating expectations by +1.20%.
Earnings released on 6 Nov 2025
EPS came in at -$0.16 falling short of the estimated -$0.09 by -77.78%, while revenue for the quarter reached $87.31m , missing expectations by -47.12%.
Earnings released on 5 Aug 2025
EPS came in at -$0.02 surpassing the estimated -$0.17 by +88.24%, while revenue for the quarter reached $82.39m , missing expectations by -0.10%.
Earnings released on 6 May 2025
EPS came in at -$0.21 falling short of the estimated -$0.18 by -16.67%, while revenue for the quarter reached $65.00m , beating expectations by +6.15%.
Earnings released on 4 Mar 2025
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $69.11m , beating expectations by +33.68%.
Earnings released on 7 Nov 2024
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%, while revenue for the quarter reached $51.63m , missing expectations by -16.12%.
Earnings released on 12 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.15 by +66.67%, while revenue for the quarter reached $73.83m , beating expectations by +50.50%.
Earnings released on 7 May 2024
EPS came in at $0.34 surpassing the estimated $0.05 by +580.00%, while revenue for the quarter reached $137.74m , beating expectations by +62.98%.
Earnings released on 27 Feb 2024
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%, while revenue for the quarter reached $32.25m , beating expectations by +12.37%.
Earnings released on 7 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%, while revenue for the quarter reached $33.97m , beating expectations by +14.84%.
Earnings released on 1 Aug 2023
EPS came in at -$0.46 surpassing the estimated -$0.63 by +26.98%, while revenue for the quarter reached $25.79m , beating expectations by +4.65%.
Earnings released on 9 May 2023
EPS came in at -$0.79 falling short of the estimated -$0.65 by -21.54%, while revenue for the quarter reached $24.33m , beating expectations by +10.54%.
Earnings released on 21 Feb 2023
EPS came in at -$0.76 surpassing the estimated -$0.87 by +12.64%, while revenue for the quarter reached $18.82m , missing expectations by -8.69%.
Earnings released on 1 Nov 2022
EPS came in at -$0.81 surpassing the estimated -$0.93 by +12.90%, while revenue for the quarter reached $18.98m , missing expectations by -3.57%.
Earnings released on 2 Aug 2022
EPS came in at -$1.05 falling short of the estimated -$0.95 by -10.53%, while revenue for the quarter reached $18.84m , beating expectations by +1.21%.
Earnings released on 3 May 2022
EPS came in at -$0.93 surpassing the estimated -$0.96 by +3.12%, while revenue for the quarter reached $18.84m , beating expectations by +22.26%.
Earnings released on 22 Feb 2022
EPS came in at -$1.77 surpassing the estimated -$2.32 by +23.71%, while revenue for the quarter reached $15.40m , beating expectations by +6.36%.
Earnings released on 2 Nov 2021
EPS came in at -$2.62 surpassing the estimated -$2.86 by +8.39%, while revenue for the quarter reached $14.41m , missing expectations by -12.83%.
Earnings released on 3 Aug 2021
EPS came in at -$1.67 surpassing the estimated -$1.82 by +8.24%, while revenue for the quarter reached $40.66m , meeting expectations.
ESPR Stock Performance
Access detailed ESPR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
